Cambridge Biotech Raises $133M for Intracellular TCR Drugs
The Series B funds clinic entry for two TCR-CD3 bispecific programmes, which remain research-stage with no clinical data yet.
Updated on Nov. 5, 2026 in Biotech
T-Therapeutics closed a $133 million Series B financing, co-led by Advent Life Sciences and British Business Bank, and appointed Dr. Kirsty Crame as Chief Development Officer. The financing was oversubscribed and is research-stage: the company is entering the clinic to generate proof-of-concept data for two lead programmes rather than selling an approved product.
Why it matters
The round attracts a mix of venture funds, a large pharmaceutical company (Eli Lilly and Company), and existing backers including Sanofi Ventures and Tencent, signalling investor appetite for bispecific T-cell receptor approaches in cancer and autoimmune disease. Funding entry into the clinic is the step that will show whether the company's platform translates from preclinical work into patient data.
The financing is a $133 million Series B, and the company reports that it was oversubscribed. The round funds entry into the clinic and generation of clinical proof-of-concept data, but no efficacy or safety measurements have been reported yet.
The players
T-Therapeutics
A Cambridge, UK biotechnology company developing TCR-CD3 bispecific programmes for cancer and autoimmune disease using its proprietary OpTiMus fully human TCR platform.
Advent Life Sciences
A life sciences venture investor that co-led the $133 million Series B financing alongside British Business Bank.
British Business Bank
The UK government-owned development bank that co-led the Series B and will place a representative on T-Therapeutics' board.
Eli Lilly and Company
A major US pharmaceutical company that joined T-Therapeutics' investor group as a new investor in this financing.
Dr. Kirsty Crame
T-Therapeutics' newly appointed Chief Development Officer, formerly Chief Medical Officer at Curatis AG, with over 15 years in novel biopharmaceutical development.
The details
T-Therapeutics builds T-cell receptor (TCR) therapies, which are engineered proteins that let immune cells recognize specific targets on diseased cells. Its proprietary OpTiMus platform produces fully human TCRs, and the company says this lets it reach intracellular targets, proteins inside cells that conventional antibody drugs generally cannot access. Its TCR-CD3 bispecific programmes are designed to bind a target on a diseased cell and CD3, a protein on T cells, to direct immune attack. The company also describes selective depletion of pathogenic cells as a way to reset the immune system in autoimmune disease.
Timeline
November 5, 2026: T-Therapeutics announced the closing of its $133 million Series B financing.
The financing is intended to fund entry into the clinic for two lead programmes.
The Tech Race
CD3 bispecific engagers have established a clinical template, and T-Therapeutics' bet is that fully human TCRs built on its OpTiMus platform can reach intracellular targets beyond that template. Whether this positions the company against established bispecific developers will depend on clinical data from its two lead programmes, which have not yet entered the clinic.
No product is available to patients from this announcement, and the company has not disclosed clinical timelines. Patients and clinicians would only see effects if the two lead programmes generate clinical proof-of-concept data and advance through later trial stages.
The takeaway
The key trajectory is whether fully human TCRs can reach intracellular targets in patients, which only clinical data from the entry-into-clinic phase can establish. Watch for the first clinical proof-of-concept results from T-Therapeutics' two lead TCR-CD3 bispecific programmes.
Further reading
For the broader research field behind this financing, see Biotech.
